Relyea Zuckerberg Hanson LLC Trims Stock Position in Danaher Corporation $DHR

Relyea Zuckerberg Hanson LLC lowered its stake in Danaher Corporation (NYSE:DHR) by 41.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,122 shares of the conglomerate’s stock after selling 783 shares during the period. Relyea Zuckerberg Hanson LLC’s holdings in Danaher were worth $222,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of DHR. Vanguard Group Inc. increased its stake in Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after buying an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after acquiring an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after acquiring an additional 194,466 shares during the period. Invesco Ltd. lifted its position in Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Danaher by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after purchasing an additional 163,332 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Wells Fargo & Company cut their price objective on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 23rd. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a report on Saturday, September 27th. Guggenheim reaffirmed a “buy” rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Barclays reiterated an “overweight” rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $245.91.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Performance

NYSE:DHR opened at $211.65 on Tuesday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $151.55 billion, a P/E ratio of 45.03, a price-to-earnings-growth ratio of 3.06 and a beta of 0.77. The firm has a 50-day moving average price of $200.36 and a two-hundred day moving average price of $197.24. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s payout ratio is 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.